UPDATE: Loewen Ondaatje McCutcheon Downgrades BioMimetic Therapeutics to Hold, Reiterates $7.50 PT
In a report published Wednesday, Loewen Ondaatje McCutcheon downgraded its rating on BioMimetic Therapeutics (NASDAQ: BMTI) from Buy to Hold, but reiterated its $7.50 price target.
Loewen Ondaatje McCutcheon noted, “With BMTI trading within proximity of our 12-month price target of $7.50 per share, we have downgraded the shares to Hold (from Buy), reflecting a more balanced risk/reward profile.”
BioMimetic Therapeutics closed on Tuesday at $6.94.
Latest Ratings for BMTI
|Mar 2013||Wells Fargo||Terminates||Neutral|
|Nov 2012||Loewen, Ondaatje, McCutcheon||Downgrades||Buy||Hold|
|Oct 2012||Loewen, Ondaatje, McCutcheon||Initiates Coverage on||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.